ReviewThe Lancet. Infectious diseases2025
Review of the WHO guideline on preventive chemotherapy for public health control of strongyloidiasis.
Review in The Lancet. Infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Surveillance and sociodemographic risk profiling of human soil-transmitted helminth infections in Gabon, Central Africa.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2026Article
- Evaluation of the diagnostic performance of a commercial ELISA based on two recombinant antigens for the diagnosis of Strongyloides stercoralis infection.Parasites & vectors · 2026Article
- A case of severe strongyloidiasis complicating immunosuppressive therapy initiated for IgA vasculitis.Parasites, hosts and diseases · 2026Article
- Investigation of Donor-Transmitted Strongyloides stercoralis Infections in Solid Organ Transplant Recipients, United States, 2012-2024.Emerging infectious diseases · 2026Article
- Strongyloides stercoralis infection in patients presenting with lower respiratory tract infections: a retrospective case series from a tertiary hospital in Vietnam.BMC infectious diseases · 2026Article
- Infectious Risks Associated with Biologic Therapies in Autoimmune, Rheumatologic and Dermatologic Diseases: A Narrative Review.Microorganisms · 2026Review
- Colonic Strongyloides stercoralis With Multimodality Imaging, Endoscopic, and Histopathologic Correlation.Cureus · 2026Article
- Heavy burden of soil-transmitted helminth infections in a remote and impoverished indigenous community of Honduras revealed by real time polymerase chain reaction.Infectious diseases of poverty · 2026Article
- Prevalence of Strongyloides stercoralis in haemodialysis patients in Vienna.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Article
- Strongyloidiasis Beyond the Tropics: Updated Epidemiological Evidence from a Historically Endemic Region in Spain.Tropical medicine and infectious disease · 2026Article
- Retrospective screening reveals the rare occurrence of zoonoticParasitology · 2026Article
- Towards effective coverage of Chagas disease: a community-based approach in migrant populations.International journal for equity in health · 2026Article
- Donor Screening Failure for Strongyloides stercoralis in Solid Organ Transplantation.Emerging infectious diseases · 2026Article
- Clinical Insights intoInfection and drug resistance · 2026Article
- Transgenesis and targeted mutagenesis in the human-parasitic nematodeFrontiers in parasitology · 2026Review
- Duodenal Strongyloidiasis Mimicking Inflammatory Bowel Disease: A Case Report of a 52-Year-Old Immunocompetent Woman.Clinical medicine insights. Case reports · 2026Article
- Article
- Sexually transmitted enteric infections in men who have sex with men.Clinical microbiology reviews · 2025Review
- Notes on the threadwormInternational journal for parasitology. Parasites and wildlife · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Strongyloidiasis is a soil-transmitted helminthiasis that is estimated to affect 300-600 million people across Asia, Africa, South and central America, and the Pacific. This neglected parasitic disease is most known for its ability to persist as a lifelong infection due to autoinfection and its risk of hyperinfection and disseminated disease during immunosuppression, which has a more than 60% case fatality. Despite the large global burden of strongyloidiasis, there have been no large-scale public health programmes or WHO guidelines directed towards its control and elimination. However, over the past decade, key scientific and policy changes along with requests from endemic countries have led to WHO incorporating strongyloidiasis into its 2021-30 roadmap and public health targets for control and elimination of neglected tropical diseases. In 2024, WHO published its first guideline on public health control of strongyloidiasis with a single recommendation: in endemic settings with a Strongyloides stercoralis infection prevalence of 5% or higher (measured either with Baermann or agar plate culture from stool specimens), WHO conditionally recommends mass drug administration with single-dose ivermectin (200 μg/kg; oral therapy) in all age groups from 5 years and older to reduce strongyloidiasis. This Review, written by the 2023-24 strongyloidiasis guidelines development group along with WHO colleagues and international experts, presents a summary of the recently published WHO guideline recommendation for strongyloidiasis, and the supporting evidence, considerations for public health implementation, and future research needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.